The experimental drug apixaban (Eliquis), which is being developed by Bristol-Myers Squibb (NYSE: [[ticker:BMY]]) and Pfizer (NYSE: [[ticker:PFE]]), met key endpoints in a pivotal Phase 3 trial, according to a press release. The companies plan to apply for approval to market the drug in patients with atrial fibrillation, both in the U.S. and Europe, by the end of the year. Bristol’s stock was up nearly 5 percent in morning trading, reaching $29.30, while Pfizer shares rose 2 percent to $20.78.
Author: Arlene Weintraub
Arlene is an award-winning journalist specializing in life sciences and technology. She was previously a senior health writer based out of the New York City headquarters of BusinessWeek, where she wrote hundreds of articles that explored both the science and business of health. Her freelance pieces have been published in USA Today, US News & World Report, Technology Review, and other media outlets. Arlene has won awards from the New York Press Club, the Association of Health Care Journalists, the Foundation for Biomedical Research, and the American Society of Business Publication Editors. Her book about the anti-aging industry, Selling the Fountain of Youth, was published by Basic Books in September 2010.
View all posts by Arlene Weintraub
